Comments
UCB's next generation drugs take over after blockbuster expiry
29.10.2012. | BRUSSELS (Reuters) - Belgian pharmaceuticals group UCB said on Monday that sales of its three new main products had for the first time overtaken those of its expiring blockbuster epilepsy treatment Keppra and retained its full-year guidance....
